antisense therapy (Ben Gurion University)

N/A

Report date: 2025/01/26 18:03:35
NME

Base Information

Drug Nameantisense therapy (Ben Gurion University)
Drug Alias Nameantisense therapy (BioLineRx/Ben Gurion University)BL-3030
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCytosolic phospholipase A2 inhibitors
TargetsCytosolic phospholipase A2
Therapy Area/IndicationsInflammationAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBen-Gurion University of the Negev
China Registration ClassN/A

Develop Information

Active CompaniesBen-Gurion University of the Negev
Inactive CompaniesBiolinerx Ltd
Active IndicationsInflammationAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A